Nilotinib will be administered twice daily at a dose of 400 mg (800 mg/day) for 1 year.

3 trials

Sponsors

Tokyo STI Study Group, East Japan CML Study Group (EJCML), Nara Hospital Kinki University School Of Medicine

Conditions

Chronic myelogenous leukemia

Phase 2

A phase 2 multicenter clinical study evaluating the safety and efficacy of Nilotinib in patients with Imatinib- resistant/intolerant CML in chronic phase

JPRN-UMIN000001927

Tokyo STI Study GroupChronic myelogenous leukemia

Start: 2009-04-01Target: 50Updated: 2026-06-29

Prospective multicenter clinical study evaluating efficacy and safety of Nilotinib in Ph chromosome-positive (Ph+) CML patients with Imatinib resistance or intolerance

Active, not recruitingJPRN-UMIN000002201

East Japan CML Study Group (EJCML)Chronic myelogenous leukemia

Start: 2009-03-06Target: 40Updated: 2026-06-29

Clinical study evaluating efficacy of Nilotinib in CML patients

RecruitingJPRN-UMIN000002579

Nara Hospital Kinki University School Of MedicineChronic myelogenous leukemia

Start: 2009-06-01Target: 20Updated: 2026-06-29

Related Papers

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.

2014-03-2018 citations